Cost Per Response of Certolizumab Pegol Versus Adalimumab Among Biologic-Naïve Patients With Moderate or Severe Rheumatoid Arthritis from the US Payer Perspective
Abstract
Authors
A Chua E Lee P Ralston M Sénécal J Stark R Liu M Yassine R Low Y Sun